MiNK Therapeutics (FRA:6Q40) Total Operating Expense: €11.04 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Q40 MiNK Therapeutics Inc FRA:6Q40
21 GF Score
Price €8.75
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics Total Operating Expense?

MiNK Therapeutics FRA:6Q40 -2.78% 21 Total Operating Expense is €11.04 Mil as of Mar. 2026. GuruFocus rates FRA:6Q40 with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

MiNK Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was €2.49 Mil. MiNK Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €11.04 Mil.

MiNK Therapeutics Total Operating Expense Related Terms

MiNK Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics Total Operating Expense Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 16.47 29.22 21.02 10.17 10.66

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 3.20 2.55 2.80 2.49
FRA:6Q40
21GF Score
MiNK Therapeutics Inc FRA:6Q40
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €11.04 Mil mean?
MiNK Therapeutics (FRA:6Q40) has a Total Operating Expense of €11.04 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on MiNK Therapeutics and its competitors.
Is MiNK Therapeutics' Total Operating Expense too high?
MiNK Therapeutics' current Total Operating Expense is €11.04 Mil. Overall, MiNK Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' Total Operating Expense compare to BOLD and FLNA?
MiNK Therapeutics' Total Operating Expense of €11.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current Total Operating Expense is €11.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (FRA:6Q40) has a current Total Operating Expense of €11.04 Mil. The current Total Operating Expense is €11.04 Mil. MiNK Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For MiNK Therapeutics (FRA:6Q40), the current Total Operating Expense is €11.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges INKT:USA
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
21GF Score

Get the complete analysis for FRA:6Q40

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.75
Price